Orkambi® (lumacaftor/ivacaftor) – Expanded indication and new dosage form
September 28, 2016 – Vertex announced the FDA approval of Orkambi (lumacaftor/ivacaftor), for the treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene.
Top